A phase Ib trial investigating huperzine-A in (BIS-001) in patients with refractory epilepsy
Phase of Trial: Phase I
Latest Information Update: 09 May 2017
At a glance
- Drugs Huperzine A (Primary)
- Indications Complex partial epilepsy
- Focus Adverse reactions; Proof of concept
- 09 May 2017 According to Biscayne Pharmaceuticals media release, the company reported that the Australian regulatory authorities have cleared Biscayne to begin a Phase 1b trial of BIS-001 at the Royal Melbourne Hospital, enrollment is expected to commence in the coming weeks.
- 24 Oct 2016 According to Biscayne Pharmaceuticals media release, company expects to advance this study in mid-2017.
- 28 Jun 2016 According to Biscayne Pharmaceuticals media release, company plans to initiate this study later this year.